期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

晚期结直肠癌抗表皮生长因子受体靶向治疗生物标志物 被引量：2

下载PDF
导出
摘要 结直肠癌为临床常见恶性肿瘤之一，在西方国家位列肿瘤死亡率的第2位，在我国位列第4位。分子靶向治疗是结直肠癌除外科手术、放疗和化疗之外的一种新的治疗手段，
作者 孙昭 白春梅
机构地区 中国医学科学院北京协和医学院北京协和医院肿瘤内科
出处 《协和医学杂志》 2010年第2期201-205,共5页 Medical Journal of Peking Union Medical College Hospital
关键词 结直肠癌 表皮生长因子受体 单克隆抗体 生物学标志物
分类号 R735.3 [医药卫生—肿瘤]
  • 相关文献

参考文献24

  • 1庄荣源,刘天舒,周宇红,金文,崔越宏,陈勇,王志明.西妥昔单抗联合化疗治疗转移性结直肠癌疗效与K-ras状态的关系[J].中国癌症杂志,2009,19(12):943-946. 被引量：6
  • 2Siena S,Sartore-Bianchi A,Di Nicolantonio F,et al.Bio-markers predicting clinical outcome of epidermal growth fac-tor receptor-targeted therapy in metastatic colorectal cancer. Journal of the National Cancer Institute . 2009
  • 3Van Cutsem E,Siena S,Humblet Y,et al.An open-label,single-arm study assessing safety and efficacy of panitumum-ab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Annals of Oncology . 2008
  • 4McCubrey JA,Steelman LS,Chappell WH,et al.Roles of the Raf/MEK/ERKpathway in cell growth,malignant trans-formation and drug resistance. Biochimica et Biophysica Acta . 2007
  • 5McCubrey JA,Steelman LS,Abrams SL,et al.Roles of the RAF/MEK/ERK and PI3K/PTEN/AKTpathways in malig-nant transformation and drug resistance. Advances in Enzyme Regulation . 2006
  • 6Bokemeyer C,Bondarenko I,Hartmann JT,et al.K-RAS status and efficacy of first-line treatment of patients with me-tastatic colorectal cancer with FOLFOX with or without cetuximab:the OPUS experience(abstract). Journal of Clinical Oncology . 2008
  • 7Di Nicolantonio F,Martini M,Molinari F,et al.A wild-type BRAFis required forresponse to panitumumab orcetux-imab in metastatic colorectal cancer. Journal of Clinical Oncology . 2008
  • 8Razis E,Briasoulis E,Vrettou E,et al.Potential value of PTEN in predicting cetuximab response in colorectal cancer:an exploratory study. BMC Cancer . 2008
  • 9Francoual M,Etienne-Grimaldi MC,Formento JL,et al.EGFR in colorectal cancer:more than a simple receptor. Annals of Oncology . 2006
  • 10Jacobs B,De Roock W,Piessevaux H,et al.Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetux-imab. Journal of Clinical Oncology . 2009

二级参考文献8

  • 1Harari PM. Epidermal growth factor receptor inhibition strategies in ontology [ J ] . Endocr Relat Cancer, 2004,11 (4):689-708.
  • 2Cunningham D, Humblat Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectat cancer [ J ] . New Engl J Med, 2004,351 (4):337-345.
  • 3Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer [J]. J Clin Oncol, 2008, 26(14):2311-2319.
  • 4Bokemeyer C, Bondarenko I, Makhson A, et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study [ J ] . J Clin Oneol, 2007,25(18 Suppl):4035.
  • 5Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinoteean and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial [ J ] . J Clin Oncol, 2007, 25(18):4000.
  • 6Van Cutsem E, kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer [ J ] . N Engl J Med, 2009, 360:1408-1417.
  • 7Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplafin with and without eetuximab in the first-line treatment of metastatic colorectal cancer [ J ] . J Clin Oncol, 2009,27:663-671.
  • 8http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx.

共引文献5

同被引文献27

引证文献2

二级引证文献34

协和医学杂志
2010年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部